David M. Ross

7.0k total citations · 1 hit paper
143 papers, 3.0k citations indexed

About

David M. Ross is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, David M. Ross has authored 143 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Hematology, 106 papers in Genetics and 42 papers in Rheumatology. Recurrent topics in David M. Ross's work include Chronic Myeloid Leukemia Treatments (91 papers), Chronic Lymphocytic Leukemia Research (56 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). David M. Ross is often cited by papers focused on Chronic Myeloid Leukemia Treatments (91 papers), Chronic Lymphocytic Leukemia Research (56 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). David M. Ross collaborates with scholars based in Australia, United States and Germany. David M. Ross's co-authors include Timothy P. Hughes, Susan Branford, David T Yeung, John F. Seymour, Andrew Grigg, Anthony K. Mills, Robin Filshie, Anthony P. Schwarer, Christopher Arthur and Deborah L. White and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

David M. Ross

129 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers

Countries citing papers authored by David M. Ross

Since Specialization

Citations

This map shows the geographic impact of David M. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Ross more than expected).

Fields of papers citing papers by David M. Ross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Ross. The network helps show where David M. Ross may publish in the future.

Co-authorship network of co-authors of David M. Ross

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Ross. A scholar is included among the top collaborators of David M. Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Ross. David M. Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities 2025 ·Cancers ·(unknown), David M. Ross, Deborah L. White, Timothy P. Hughes, Ilaria S. Pagani	0
2	High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine 2024 ·Blood ·(unknown), Nirmal Robinson, Monika Kutyna, Kelly Lim, (unknown), Steven Lane, David T Yeung, Agnes S. M. Yong, David M. Ross, Devendra Hiwase, Danièl Thomas	2
3	Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis 2024 ·Blood ·(unknown), Prithviraj Bose, Hsin‐An Hou, Wojciech Homenda, David M. Ross, Sanjay Mohan, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Andrew C. Perkins, (unknown), (unknown), (unknown), Jesse McGreivy, Wayne Rothbaum, Srđan Verstovšek, Alessandro M. Vannucchi	3
4	Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine 2024 ·Blood ·Devendra Hiwase, David M. Ross, David T Yeung, Agnes S. M. Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy P. Hughes, John Reynolds, Danièl Thomas	2
5	CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting 2024 ·PLoS ONE ·Kelly Lim, Winnie L. Kan, Pramod C. Nair, Monika Kutyna, Angel F. López, Timothy R. Hercus, David M. Ross, Steven Lane, Chun Yew Fong, Anna Brown, Agnes S. M. Yong, David T Yeung, Timothy P. Hughes, Devendra Hiwase, Danièl Thomas	0
6	Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches 2023 ·Blood Cancer Discovery ·Pramod C. Nair, Jacob Piehler, Denis Tvorogov, David M. Ross, Angel F. López, Jason Gotlib, Danièl Thomas	12
7	Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry 2023 ·Pathology ·(unknown), Wendy N. Erber, Andrew Grigg, (unknown), Andrew C. Perkins, Cecily Forsyth, David M. Ross	4
8	Novel modes of MPL activation in triple-negative myeloproliferative neoplasms 2022 ·Pathology ·Saumya E. Samaraweera, Tatjana Geukens, Débora A. Casolari, (unknown), (unknown), (unknown), Sarah Moore, Jinghua Feng, Andreas Schreiber, Wendy T Parker, Anna Brown, Carolyn M Butcher, Peter Bardy, Michael J. Osborn, Hamish S. Scott, Dipti Talaulikar, Carolyn Grove, Christopher N Hahn, Richard J. D’Andrea, David M. Ross	1
9	Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR 2022 ·Journal of Molecular Diagnostics ·(unknown), Elizabeth Hughes, (unknown), David M. Ross, Matthew Greenwood, Kenneth F. Bradstock, Luciano Dalla‐Pozza, (unknown), Tamara Law, (unknown), Nicola C. Venn, Shahid Ullah, Rosemary Sutton, Alexander A. Morley	2
10	Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis 2022 ·American Journal of Hematology ·(unknown), David M. Ross, Donal P. McLornan, Krisstina Gowin, (unknown), Vikas Gupta, (unknown), Nico Gagelmann, Nada Hamad	7
11	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study 2021 ·Blood Advances ·John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El‐Galaly, Aaron T. Gerds, Vikas Gupta, Brian Higgins, (unknown), Candice Jamois, Bruno Kovic, Ling‐Yuh Huw, (unknown), Margherita Maffioli, Ruben A. Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub	16
12	Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study 2021 ·Cancer Reports ·Hilary Martin, Shahid Ullah, (unknown), (unknown), Ganessan Kichenadasse, Christos S. Karapetis, Amitesh Roy, Shawgi Sukumaran, David M. Ross, Muhammad Adnan Khattak, Bogda Koczwara	3
13	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial 2021 ·Leukemia ·Jerald P. Radich, Andreas Hochhaus, Tamás Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez‐Casares, Valentín García‐Gutiérrez, Eibhlin Conneally, Philipp D. le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saußele, Francis J. Giles, David M. Ross, Paola Aimone, Sai Li, (unknown), Giuseppe Saglio	47
14	Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells 2020 ·British Journal of Haematology ·Yazad Irani, Amy Hughes, Jade Clarson, Chung Hoow Kok, Naranie Shanmuganathan, Deborah L. White, David T Yeung, David M. Ross, Timothy P. Hughes, Agnes S. M. Yong	54
15	The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia 2019 ·Leukemia & lymphoma ·Masa Lasica, Abbey Willcox, Kate Burbury, David M. Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony K. Mills, David Simpson, Constantine S. Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg	15
16	Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis 2018 ·Science Advances ·Denis Tvorogov, Danièl Thomas, Nicholas P. D. Liau, Mara Dottore, Emma F. Barry, (unknown), Winnie L. Kan, Timothy R. Hercus, Frank C. Stomski, Timothy P. Hughes, Vinay Tergaonkar, Michael W. Parker, David M. Ross, Ravindra Majeti, Jeffrey J. Babon, Angel F. López	41
17	Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms 2017 ·Blood ·Christopher N Hahn, (unknown), Milena Babic, Jinghua Feng, Paul Wang, Monika Kutyna, Sarah Moore, Anna Brown, Richard J. D’Andrea, Deepak Singhal, Andreas Schreiber, Pratyush Giri, David M. Ross, Devendra Hiwase, Hamish S. Scott	3
18	Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience 2017 ·Blood ·Naranie Shanmuganathan, Susan Branford, David T Yeung, Devendra Hiwase, Agnes S. M. Yong, David M. Ross, Timothy P. Hughes	1
19	BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia 2016 ·Journal of Clinical Pathology ·Susan Latham, (unknown), (unknown), David M. Ross, Elizabeth Hughes, Susan Branford, Deborah L. White, Timothy P. Hughes, Alexander A. Morley	5
20	Moving treatment-free remission into mainstream clinical practice in CML 2016 ·Blood ·Timothy P. Hughes, David M. Ross	227

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact